NCT05460273 · OUTCOME

Immunogenicity of Dato-DXd

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · Source last updated 2026-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage
Interval / dispersion: Not reported
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

What was measured

The prevalence of ADA (positive at any visit)

Analysis population: ADA Evaluable Set: Participants in the FAS with a non-missing baseline Dato-DXd ADA result and at least one post-baseline Dato-DXd ADA result.

Groups in this outcome

TNBC Cohort

Final Analysis with DCO on 06May2024

NSCLC Cohort

Final Analysis with DCO on 27Nov2024

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
TNBC Cohort	75
NSCLC Cohort	38

Reported measurements

Source class 1

Values in percentage · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
TNBC Cohort	33.3	Not reported	Not reported	Not reported	Not reported
NSCLC Cohort	36.8	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
33.3
group Id
OG001
value
36.8

denoms

counts
group Id
OG000
value
75
group Id
OG001
value
38
units
Participants

description

The prevalence of ADA (positive at any visit)

groups

description
Final Analysis with DCO on 06May2024
id
OG000
title
TNBC Cohort
description
Final Analysis with DCO on 27Nov2024
id
OG001
title
NSCLC Cohort

param Type

NUMBER

population Description

ADA Evaluable Set: Participants in the FAS with a non-missing baseline Dato-DXd ADA result and at least one post-baseline Dato-DXd ADA result.

reporting Status

POSTED

time Frame

TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

title

Immunogenicity of Dato-DXd

type

SECONDARY

unit Of Measure

percentage

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice